Takeda Takes Back Dravet, Lennox-Gastaut Candidate From Ovid

 
• By Joseph Haas

Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.

Female athletes running towards finish line on track field
Ovid will let Takeda take soticlestat to the finish line

More from Deals

More from Business